Page 11 - Alkermes News Today

Alkermes plc (NASDAQ:ALKS – Get Free Report) has earned a consensus rating of “Moderate Buy” from the eight brokerages that are presently covering the firm, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price objective among […]

Addiction Recovery Care announced ARC Healthcare Chief Operating Officer Pat Fogarty will see a role expansion.

Topline results from a pivotal phase 3, open-label extension study showcase the long-term safety and efficacy of olanzapine and samidorphan (Lybalvi) in patients with schizophrenia, schizophreniform disorder, or bipolar I disorder.

18.01.2024 - Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) is saddened to announce the passing of its former President, Srdjan (Serge) Stankovic M.D., M.S.P.H. Serge passed away peacefully on December 29, 2023, following a prolonged illness. “Serge” as he was known ...

StockNews.com began coverage on shares of Alkermes (NASDAQ:ALKS – Free Report) in a research report report published on Tuesday. The brokerage issued a strong-buy rating on the stock. A number of other brokerages have also recently issued reports on ALKS. Mizuho reduced their price objective on Alkermes from $37.00 to $35.00 and set a buy […]

StockNews.com assumed coverage on shares of Alkermes (NASDAQ:ALKS – Free Report) in a research report report published on Tuesday morning. The brokerage issued a strong-buy rating on the stock. A number of other equities analysts have also recently issued reports on the company. Piper Sandler dropped their target price on Alkermes from $37.00 to $35.00 […]

Alkermes (NASDAQ:ALKS – Free Report) had its price objective boosted by Bank of America from $27.00 to $29.00 in a research note issued to investors on Tuesday, Benzinga reports. Bank of America currently has a neutral rating on the stock. A number of other research firms have also recently weighed in on ALKS. StockNews.com raised […]

A study demonstrated olanzapine and samidorphan’s (LYBALVI) safety, tolerability, and durability during a 4-yeat treatment period.

The data assess the extended efficacy of the treatment for up to 4 years.

Alkermes plc (ALKS) reported topline results from a phase 3, open-label extension study assessing the long-term safety, tolerability and durability of treatment effect of LYBALVI in patients with schizophrenia, schizophreniform disorder or bipolar I disorder for up to four years of treatment, following treatment received in prior LYBALVI studies.